Clinical Trial Update: Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells [Phase 1]

View source ↗

Summary

This completed Phase 1 study evaluated an autologous CD40 ligand approach combined with IL-2-expressing tumor cells for chronic lymphocytic leukemia to assess s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Autologous CD40 Ligand
• IL-2-Expressing Tumor Cells

Snippet

Sponsor: Baylor College of Medicine | Conditions: Chronic Lymphocytic Leukemia (CLL) | Phase 1 | Status: COMPLETED